Physicians' Academy for Cardiovascular Education

CardioVascular Risk Master Class

Dubai, Friday May 24, 2013

10' education - May 17, 2013

An educational alliance to optimize management of cardiovascular disease

Attend live webcast

This Master Class program is a global initiative of the Physicians’ Academy for Cardiovascular Education(PACE) foundation with a particular focus on issues and opportunities in cardiovascular risk and lipid management in high risk patients.

The online live webcast will start on:

Friday, May 24 at 15:00 hrs - (Dubai time)

Click here to start e-learning - webcast

For online participation a logon and password is needed
(this is separate from PACE member log-on)

Register for live access to this Master Class, contact PACE to receive a participant code via this link

Participants will not only be educated on the new science and clinical perspective in lipid and CV risk management but also engage in educational activities. Therefore a part of the master class will be dedicated on specific support and educational tools for facilitation of regional medical education initiatives. Teaching resources are  available on the PACE website. See here
The conferences are sponsored by an unrestricted educational grant provided by Pfizer



Friday, May 24, 2013

15:15 – 15:50
The challenge for CV Risk management in Middle East, Africa & Eastern Europe: Opportunities for early intervention
John Deanfield, MD UCL, London, United Kingdom

16:00 – 16:25
Statin therapy: a landmark in vascular medicine
John Kastelein, MD, Academic Medical Centre, Amsterdam, The Netherlands

17:20 – 17:55
Latest insights from clinical trials: The unassailable case for LDL-c lowering & statin therapy
Kees Hovingh, MD, Academic Medical Centre, Amsterdam, The Netherlands

18:05 – 18:40
How does BP lowering prevent the clinical manifestations of CV disease?
Richard Hobbs, MD, University of Oxford, United Kingdom

Start video

The information and data provided in this program were updated and correct at the time of the program development, but may be subject to change.

Share this page with your colleagues and friends: